Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rh-Endostatin + Radiotherapy in HCC
NCT03208335Phase 2
Key facts
- Status
- Unknown
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Countries
- 1
- Sponsor
- Chinese PLA General Hospital
- Modality
- rProtein (Recombinant Protein), Biologic
- Drugs
- endostar
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of endostar in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-Free Survival at 18 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
rh-endostatin combination
rh-endostatin + Radiotherapy
03
Who it enrols
Patients with histologically or cytologically confirmed HCC, or radiographic indicative HCC with AFP > 250 ug/l, who are inoperable and untransplantable, with Child-Pugh A or B and PS 0-1.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Response Rate
Clinical Benefit Rate
Overall Survival
Adverse Events
Quality of Life
Beyond the preview
Go deeper on NCT03208335.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208335.